Human Reproduction, Vol. 12, No. 11, pp. 2359-2365, 1997
© 1997 European Society of Human Reproduction and Embryology
Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients
The Center for Reproductive Medicine and Infertility, The New York Hospital–Cornell Medical Center New York, NY 10021, USA
Correspondence: 1To whom correspondence should be addressed at: Division of Reproductive Endocrinology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Certain patients have a tendency for high response to gonadotrophin therapy which is often not ameliorated with prior gonadotrophin-releasing hormone agonist (GnRHa) suppression. As a result, these patients are frequently cancelled and often experience ovarian hyperstimulation syndrome (OHSS) episodes during in-vitro fertilization (IVF)–embryo transfer cycles. Patients with polycystic ovarian syndrome (PCOS) have been noted to be particularly sensitive to exogenous gonadotrophin therapy. We have developed a protocol which is effective in improving IVF outcome in high responder patients, including those with PCOS. Oral contraceptive pills (OCP) are taken for 25 days followed by s.c. leuprolide acetate, 1 mg/day, which is overlapped with the final 5 days of oral contraceptive administration. Low-dose gonadotrophin stimulation is then initiated on the third day of withdrawal bleeding in the form of either human menopausal gonadotrophins or purified urinary folliclestimulating hormone at a dosage of 150 IU/day. Over a 5 year period, we reviewed our experience utilizing this dual method of suppression in 99 cycles obtained in 73 high responder patients. There were only 13 cancellations prior to embryo transfer (13.1%). The clinical and ongoing pregnancy rates per initiated cycle were 46.5 and 40.4% respectively. Only eight patients experienced mild-moderate OHSS following treatment. For those patients who had undergone previous IVF–embryo transfer cycles at our centre, significant improvements were noted in oocyte fertilization rates, embryo implantation rates and clinical/ongoing pregnancy rates with this protocol. Hormonal analyses revealed that the chief mechanism may be through an improved luteinizing hormone/follicle-stimulating hormone ratio following dual suppression. An additional feature of this dual method of suppression is significantly lower serum androgen concentrations, particularly dehydroepiandrosterone sulphate.
Key words: gonadotrophin-releasing hormone agonist/high responder/in-vitro fertilization/oral contraceptives/polycystic ovarian syndrome
Submitted on December 30, 1996; accepted on August 7, 1997.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. Martinez, M. Boada, B. Coroleu, E. Clua, N. Parera, I. Rodriguez, and P.N. Barri A prospective trial comparing oocyte donor ovarian response and recipient pregnancy rates between suppression with gonadotrophin-releasing hormone agonist (GnRHa) alone and dual suppression with a contraceptive vaginal ring and GnRH Hum. Reprod., August 1, 2006; 21(8): 2121 - 2125. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Macklon, R. L. Stouffer, L. C. Giudice, and B. C. J. M. Fauser The Science behind 25 Years of Ovarian Stimulation for in Vitro Fertilization Endocr. Rev., April 1, 2006; 27(2): 170 - 207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Kolibianakis, E. G. Papanikolaou, M. Camus, H. Tournaye, A. C. Van Steirteghem, and P. Devroey Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial Hum. Reprod., February 1, 2006; 21(2): 352 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.A. Damario, T.G. Lesnick, B.A. Lessey, A. Kowalik, E. Mandelin, M. Seppala, and Z. Rosenwaks Endometrial markers of uterine receptivity utilizing the donor oocyte model Hum. Reprod., September 1, 2001; 16(9): 1893 - 1899. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ludwig, D.F. Finas, S. Al-Hasani, K. Diedrich, and O. Ortmann Oocyte quality and treatment outcome in intracytoplasmic sperm injection cycles of polycystic ovarian syndrome patients Hum. Reprod., February 1, 1999; 14(2): 354 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.G. Edwards and H. K. Beard Is the success of human IVF more a matter of genetics and evolution than growing blastocysts? Hum. Reprod., January 1, 1999; 14(1): 1 - 6. [Full Text] [PDF]
|
|
|
|
|
|
M. Fukuda, K. Fukuda, C. Yding Andersen, and A. Grete Byskov Anovulations in an ovary during two menstrual cycles enhance the pregnancy potential of oocytes matured in that ovary during the following third cycle Hum. Reprod., January 1, 1999; 14(1): 96 - 100. [Abstract] [Full Text] [PDF]
|
|